|Chile Diagnostic Imaging Market Outlook to 2022 - Angio Suites, Bone Densitometers, Computed Tomography (CT) Systems, Contrast Agents, Contrast Media Injectors, Mammography Equipment, Mobile C-Arms, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems, X-ray Systems|
What is covered in the report about the "Chile Diagnostic Imaging Market"? GlobalData's "Chile Diagnostic Imaging Market Outlook to 2022" report is a comprehensive databook report, covering key market data on the Chile Diagnostic Imaging market. The databook report provides value (USD) and volume (units) within market categories - Angio Suites, Bone Densitometers, Computed Tomography (CT) Systems, Contrast Agents, Contrast Media Injectors, Mammography Equipment, Mobile C-Arms, MRI Systems, Nuclear Imaging Equipment, Ultrasound Systems and X-ray Systems . Note: This is an on-demand report and will be delivered within 2-3 business days of the purchase (excluding weekends). The Chile Diagnostic Imaging Market report provides key information and data on: - Annualized market revenues (USD) and volume (units) data for each of the market segments. Data is provided from 2008 to 2015 and forecast to 2022. - 2015 distribution share data for Diagnostic Imaging market. - Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report. Chile Diagnostic Imaging is segmented as follows: - Angio Suites - Bone Densitometers - Computed Tomography (CT) Systems - Contrast Agents - Contrast Media Injectors - Mammography Equipment - Mobile C-Arms - MRI Systems - Nuclear Imaging Equipment - Ultrasound Systems - X-ray Systems Key Reasons to Purchase The Chile Diagnostic Imaging Market report helps you to develop: - Business strategies by identifying the key market segments poised for strong growth in the future. - Market-entry and market expansion strategies. - Design competition strategies by identifying who-stands-where in the market. - Develop investment strategies by identifying the key market segments expected to register strong growth in the near future. - Understand the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize. The GlobalData Differentiation Extensive interviews are conducted with industry experts to validate the market size, company share and distribution share data and analysis. The data and analysis within this report are driven by GlobalData Medical Equipment (GDME) databases. GlobalData Medical Equipment database gives you the key information required to drive sales, investment and deal-making activity in your business. It includes the following: - 15,000+ data tables showing market size across more than 780 medical equipment segments and 39 countries, from 2008 and forecast to 2022 - 10,000+ primary interviews, conducted annually to ensure data and report quality - Approximately 4,000+ medical equipment conference reports, industry-leading analysis reports covering growing sectors, market trends, investment opportunities and competitive landscape - 600+ medical equipment trends and issues, and investment and M&A trends - 56,000+ medical equipment company profiles - 4,300+ company profiles of medical equipment manufacturers in China and India - 2,000+ company profiles of medical equipment manufacturers in Japan - 825+ companies' revenue splits and market shares - 1,900+ quarterly and annual medical equipment company financials - 940+ medical equipment company SWOTs - 21,500+ pipeline product profiles - 34,500+ marketed product profiles - 36,000+ clinical trials - 36,500+ trial investigators - 20,600+ product patents - 3,700+ reports on companies with products in development - 21,500+ reports on deals in the medical equipment industry - 1,300+ surgical and diagnostic procedures by therapy area - 50+ key healthcare indicators by country For more information or to receive a free demonstration of the service, please visit:
|Global Health Care Analytical Testing Services Market Size, Status and Forecast 2025|
This report studies the global Health Care Analytical Testing Services market, analyzes and researches the Health Care Analytical Testing Services development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Exova Group PLC Pace Analytical Services Inc Intertek Group PLC Bioreliance Corporation (Merck KGAA) Source Bioscience Envigo Anabiotec Medistri SA Eurofins Scientific SE SGS Charles River Laboratories International Inc WUXI Pharmatech (Cayman) Inc PPD Inc Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, the product can be split into Physical Characterization Services Method Validation Raw Material Testing Batch Release Testing Services Stability Testing Environmental Monitoring Microbial Testing Market segment by Application, Health Care Analytical Testing Services can be split into Medical Device Companies Pharmaceutical Companies If you have any special requirements, please let us know and we will offer you the report as you want.
|Global Real Time Health Monitoring Devices Market Professional Survey Report 2017|
This report studies Real Time Health Monitoring Devices in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering GE Healthcare (U.K.) Qualcomm (U.S.) Jawbone Inc (U.S.) Withings SA (France) Fitbit Inc (U.S.) Garmin Ltd (Switzerland) ... On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Wearable Devices Home Health Medical Devices By Application, the market can be split into Hospitals Clinics Ambulatory Centers Homecare Settings By Regions, this report covers (we can add the regions/countries as you want) North America China Europe Southeast Asia Japan India If you have any special requirements, please let us know and we will offer you the report as you want.
|Global Smart Healthcare Management System Market 2017|
Global Smart Healthcare Management System Market 2017 The Smart Healthcare Management System Market report presents an overview of the historical growth trail along with the present situation and future progress of Market. It further guesstimates the volume and revenue growth of the global market. The study also evaluates the key competitors in the market and their shares, strategies, and products. To offer a clear understanding of the Global Market, the study thoroughly analyzes the competitive landscape With all the assembled information analyzed using SWOT analysis, there is an unmistakable comprehension of the financial landscape of the Global Smart Healthcare Management System Market. The point of view for the development of the market was revealed and out-of-the-way economical threats additionally wound up clearly apparent. There is an apparent intentional direction in the market and this is witnessed in the noteworthy trends and improvements examined. By achieving market foundation and using fundamental standards, approaches, and patterns of other huge markets for documentation, market information was distinguished. The first section of the research report defines the product and presents its various classifications. The several applications of Global Smart Healthcare Management System Market have been further discussed in this section. The status of the key regions along with the industry chain structure and industry policies have been highlighted here. The second chapter offers an outlook of the manufacturing cost structure, key raw material suppliers, price of raw materials, equipment suppliers, and cost of labor. The prime regions covered in this report are North America, APAC, LMEA, and Europe. Top Key Vendors: IBM Corporation, Cerner Corporation, Verisk Analytics, Allscripts Health Solutions and Health Catalyst. The reportâ€™s conclusion reveals the overall scope of the Global Smart Healthcare Management System Market in terms of feasibility of investments in the various segments of the market, along with a descriptive passage that outlines the feasibility of new projects that might succeed in the market in the near future.
|Biosimilars on the Cusp of a New Era|
Description The biosimilars market is undergoing rapid change with developments such as the recent approvals of infliximab and trastuzumab heralding a new era. In order to keep up with the pace of change in the marketplace, regulatory agencies have been developing updated guidance around the development and approval of biosimilars, but there is still a lack of consistency, particularly between the two leading agencies â€“ the FDA and EMA. Moreover, there are some concerns around biosimilar use, for example with physicians worried about how similar certain drugs are and whether they can safely be used in particular patient populations such as transplant, due to the potential for variance in efficacy and tolerability. Despite this, it is expected that the biosimilar market will continue to experience significant growth in the next five to ten years, being driven by the extensive pipeline and the number of companies becoming involved in this area â€“ including some big pharma who are seizing the opportunity to develop biosimilar versions of competitor products in order to ensure they are able to compete at all levels. Scope The report covers the following key areas An overview and background about biosimilars â€“ what they are and a timeline of their development Key concerns regarding the development and use of biosimilars An overview of the issues around automatic substitution with biosimilars The regulatory landscape for biosimilars, including a comparison of FDA and EMA guidelines Recent developments in the biosimilars market including the anticipated patent expiries of key biologic products and launches of new biosimilar products The position of HTA and P&R agencies on biosimilars Industry perspective on the expected impact of biosimilars The biosimilars pipeline and key future developments Key companies involved in biosimilars The way forward for industry Reasons To Buy The report will: Provide an in-depth insight into recent biosimilar regulatory developments including a comparison of the processes used in different markets and the guidance being implemented Assess the biosimilars pipeline including where development is currently focused and the potential impact new biosimilars will have on the marketplace Highlight industry opinions towards biosimilars and their expected impact in different therapy areas and how industry can meet the challenges being presented by biosimilar development and launches Provide an understanding about the key concerns around biosimilar development and use, including manufacturing concerns and issues around automatic substitution Provide an overview of the key companies involved in the biosimilar market including an analysis of where the majority of biosimilar companies are located, the markets in which they operate and the future outlook
|Telemedicine - The Future is Now for Moving Telemedicine into Mainstream Treatment|
Telemedicine is a creation of the 20th century. First used primarily for military and space applications, it has been becoming more widespread in use in recent years. There are three main types of telemedicine applications: store-and-forward, remote monitoring and interactive services. Interest in telemedicine is growing globally, particularly in the fields of teleradiology, telepathology and teledermatology. Globally, cost is seen as the major barrier to telemedicine programs. In the US, telemedicine has been promoted as a way to serve rural populations, but in the next few years it is expected to spread to a much wider patient base. A number of key challenges still need to be addressed for the use of telemedicine to become more widespread in the US. Licensing and reimbursement remain major hurdles to physician participation in telemedicine. These challenges are being addressed at the state level, with an increasing number of state legislatures taking up the issues. There is also federal legislation being looked at by Congress. Issues of FDA Regulation and possible issues of taxation also need to be clarified to help promote wider use of telemedicine. The report, â€œTelemedicine â€“ The Future is Now for Moving Telemedicine into Mainstream Treatmentâ€ was written to support both the biopharmaceutical and health care industries in understanding the use of telemedicine and preparing for the expected growth it will see in the coming years. This report provides data, analysis, and CBRâ€™s insights on this key growth market and where the challenges to it may exist. Key Reasons to Purchase This comprehensive study can be used to compare the effectiveness of the different telemedicine applications available CBRâ€™s insights and case study analysis Companies can assess the impact of health care reform on telemedicine uptake now and in the future Gain insights on the key challenges that exist to further expansion of telemedicine programs and how they can be overcome Better evaluate the potential for telepharmacy programs, a key area of opportunity for the pharmaceutical industry Utilize the insights from this study to analyze the barriers facing wider adoption of telemedicine
|Womens Health - Assessing the Need for a Targeted and Specialized Approach|
Description Many of the diseases and conditions that affect mainly women are interlinked with similar root causes; however, placing all of the pieces of the puzzle together to ensure a cohesive management strategy remains a challenge. Women's Health is a collection of multi-factorial conditions and diseases that solely affect or are more prevalent in females. Many can have a serious impact on womenâ€™s overall long-term health and quality of life. There are a number of causes of Womenâ€™s Health diseases, ranging from hormonal fluctuations associated with specific points in a womanâ€™s life through to psychological issues underpinning certain lifestyle disorders. As these causes and the courses and consequences of these diseases become better understood, the importance of targeted, specific treatment is increasingly being recognized, with some female-specific interventions now being investigated. In addition, it is becoming increasingly crucial to understand and act on the interaction between different diseases that primarily affect women, in order to ensure the most effective treatment approaches. Female cancers, particularly breast and cervical, have led the way in preventive and therapeutic approaches, creating new paths for the management of other cancers and rendering some previously highly terminal cancers manageable diseases. The advent of personalized therapy for HER2-positive breast cancer was enabled through the identification of the HER2 gene and development of targeted drugs, such as Herceptin (trastuzumab) and Tyverb (lapatinib), and the prevention of cancer through vaccination has become the norm for cervical cancer. However, the same cannot be said for other female cancers, where, in spite of identification of gene mutations, targeted therapy is still in its infancy. Despite significant advances in Women's Health, there are still a number of unmet needs, particularly for therapies that address the fundamental causes of many conditions that are specific to or more prevalent in women. The fact that women are living longer means that they are encountering a wider range of health issues. It also means that there are higher expectations in therapies and that factors such as quality of life are playing an increasingly important role. As the Women's Health environment evolves and expectations in treatment increase, easier and more straightforward therapies will be needed, and there is a particular need for drugs that either address several aspects of Women's Health or work concomitantly with others to do so. Furthermore, it is recognized that many of the different conditions that affect women are interlinked and have common root causes; however, placing all of the pieces of the puzzle together to ensure a cohesive management strategy remains a challenge. The specialists who can do this are likely to be the main points of care for Women's Health. Scope The report provides an overview of issues and trends in Women's Health, including analysis of the current market landscape and key issues driving overall treatment decisions. In addition, the report offers a view of how Women's Health is likely to evolve, including treatment practices and new approaches in the pipeline. The report covers and includes: A brief introduction to Women's Health and the key diseases and conditions that affect women, including female cancers, psychological issues, sexual dysfunction and cardiovascular disease Detailed analysis of why certain diseases affect women in different ways or in larger numbers, the impact that this has on overall health and quality of life, and current approaches to managing these conditions Analysis of the pipeline for specific Women's diseases including an overview of how personalized medicine is likely to change how certain conditions are treated An overview of how Women's Health will be managed in the future, specifically looking at how specialists will adopt a multi-disciplinary approach to ensure the holistic treatment of the â€œwhole womanâ€ Reasons To Buy Primarily, the report will allow clients to gain a strong understanding of the current landscape in Women's Health, helping them to identify and clarify market opportunities and the competitive environment. It will also allow clients to: Understand why specific diseases and conditions present differently in women and the implications for treatment and management Examine developments in Women's Health and how this has impacted on the incidence and prevalence of certain diseases, along with the overall prognosis and outcomes for women with particular conditions Assess where the key unmet needs in Women's Health exist and how these opportunities can be harnessed in future drug development Understand the different issues and challenges facing companies when developing therapies for Women's Health conditions and how these can most effectively be addressed to ensure future success
|Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future|
Summary GBI Research's latest report, "Biobanking: Developing Smart, Sustainable and Ethically Compliant Biorepositories for the Future" discusses fundamental concepts in biobanking and recent technology advancements in the field. The report also describes ethical and regulatory concerns in biobanking as well as the economic challenges and opportunities surrounding this industry. Furthermore, this report provides strategic recommendations on how to overcome some of the most critical economic, technological and ethical challenges facing this fast-growing sector. Biobanks collect human biospecimens and associated data for medical-scientific research, and organize samples and data in a systematic way for use by others. The importance of biobanks lies in determining the most effective way to store that information and make it available when required. Biobanks may collect different samples from diseased or healthy individuals in various settings. The integration of novel tools such as big data techniques, coupled with the increasing industry need for high-quality biospecimens for research, will lead to expanding biospecimen collections, ultimately resulting in the growth of this sector. Biobanks currently exist on every continent with most located in North America, followed by Europe. Australia has the highest number of biobanks in the Asia-Pacific region whilst India has the highest number of biobanks, when considering the developing economies only. The development of a biobank depends upon people's willingness to donate their samples for research and to agree to sample storage. The participation and support of the public is therefore of crucial importance as their attitude towards biobanking activities will determine the success of many of these organizations. Scope - What are the fundamentals of biobanking? - How can biobanks be classified and what are their different applications in healthcare? - What are the economic challenges faced by biobanks and how can these be overcome? - What are the most recent technology advancements in biobanking? - What role does biobanking play in drug discovery and clinical trials? - How are biobanks distributed geographically? - What are the prospects of Big Data and associated technologies within biobanking? - What are the technological and legal challenges? - What are the main healthcare opportunities that can be leveraged? - What is the public attitude towards various biobanking activities? - What are the challenges in obtaining informed consent from donors and what strategies can biobanks adopt to overcome these challenges? - What are the current ethical and regulatory challenges in biobanking? - What is the role and importance of the international charter of principles for data sharing between biobanks? - What are the main intellectual property right opportunities and challenges within biobanking? How can biobanks overcome these challenges and mitigate potential risks? - What is the need for process harmonization between biobanks? Reasons to buy This report will allow you to - - Gain insights in the biobanking industry: This report describes fundamental concepts in biobanking, biobank classification as well as economic, technological and ethical challenges surrounding these organizations. Learn how biobanks can overcome these challenges through best practice guidelines and strategic recommendations. - Understand the role of biobanks in research and development: This report demonstrates the relationship between biobanks and R&D groups. - Gain analysis on the distribution of biobanks in key regions and countries: This includes detailed analysis on the number of biobanks within each of the key regions and countries. - Review and assess recent advances in biobanking technologies: This includes technology innovations in specimen collection, storage, temperature maintenance, consumables, data handling, transportation of biospecimens, and the integration of big data technologies in biobanking activities. - Understand public views on biobanking activities: Learn about the various public concerns on biobanking, their attitude towards research, and how consent issues can be addressed through novel frameworks and technology adoption. - Assess ethics, regulations, and harmonization needs in biobanking: This in-depth report provides analysis on ethical, regulatory and harmonization requirements in the biobanking sector.
|The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects|
GBI Research's latest report "The OTC Drugs Market: Commercial Trends and Rx-to-OTC Switch Prospects" discusses trends in the over-the-counter (OTC) pharmaceuticals market and the commercial prospects for switching drugs from prescription-only to OTC status. The report assesses current market drivers and restraints, mergers and acquisitions (M&A) activity and recent regulatory developments in key national markets. Furthermore, this report analyses leading therapeutic segments in the OTC drugs market, key brands, manufacturers and the potential for new product categories to be created as more prescription-only drugs from diverse therapy areas continue to be considered for OTC approval. Detailed case studies of recent Rx-to-OTC switches provide the rationale for these switches including description of their economic and financial impact. The OTC drugs market remains highly competitive and fragmented albeit leading companies continue to consolidate their market position through high-profile and strategic acquisitions. GBI Research expects M&A to remain very active in the coming years fueled by strategic long-term commercial priorities, as companies look to increase revenues through expanded OTC portfolios. A positive regulatory outlook in key markets, due to new initiatives and frameworks looking to facilitate OTC approvals, will also prompt companies to seek access to new markets. The global OTC drugs market will continue to be largely driven by demographics, economic trends and changes in cultural attitudes towards self-medication. An increasing interest in self-medication in both developed and developing countries has been identified as a major contributor to market growth in recent years. GBI Research conducted extensive primary and secondary research efforts in order to provide a comprehensive view of the regulatory, commercial and competitive landscape in the OTC drugs market. Our new report will let you assess the most promising commercial areas in the market and help you identify key opportunities and challenges. Scope How do consumers, payers and manufacturers benefit from Rx-to-OTC switches? What are the key factors promoting the usage of OTC drugs? Current trends in the OTC drugs market What attitudes do consumers have towards OTC drugs? How are new distribution channels, technologies and education reshaping the OTC drugs market? What will be the impact of new regulatory initiatives and frameworks on future Rx-to-OTC switches in key markets? What have been the preferred types of M&A deals in the OTC drugs market in recent years? Which OTC drug manufacturers have been the most active in terms of mergers and acquisitions in recent years? What are the current regulations and frameworks established in key developed and developing markets for OTC approval and Rx-to-OTC switches? Which OTC drug product categories and drug classes have experienced the most switches in recent years? Which new products categories are expected to enter the OTC drugs market in the coming years? What has been the economic and financial impact of recent Rx-to-OTC switches? Who are the leading OTC drug manufacturers and what are their OTC segments of interest? Market analysis of the leading OTC product categories including cough, cold, and allergy, analgesics, gastrointestinal and dermatological drugs. Reasons To Buy This report will allow you to: Gain insights into the OTC drugs market and future prospects for Rx-to-OTC switches: This report comprehensively describes and assesses the commercial, regulatory and competitive landscape in this highly dynamic and lucrative industry. Understand differing regulatory frameworks for OTC drugs and Rx-to-OTC switches in key markets: This report provides insights about established regulatory processes, approval frameworks and recent developments in the US, Europe, Japan, India and China for OTC drugs. Assess M&A activity in the OTC drugs market: This report provides detailed analysis on M&A deals in recent years including trends on preferred types of deals, factors contributing to the surge in transactions and identifies the most active companies in the OTC drugs market. Assess the market for the leading OTC product categories: Our new study provides market analyses of the key product categories including revenues in key national markets, key brands, key manufacturers, market drivers, restraints, recent switches and potential candidates for future Rx-to-OTC switch.
|Evolving Pharmaceutical Marketing - Strategies: Digital as a Key Component of Multichannel Marketing|
Evolving Pharmaceutical Marketing Strategies: Digital as a Key Component of Multichannel Marketing Summary GBI Researchâ€™s latest report,"Evolving Pharmaceutical Marketing Strategies: Digital as a Key Component of Multichannel Marketing" provides a comprehensive analysis of the changing pharmaceutical marketing landscape in the digital age. While the pharmaceutical industry readily adopts new technologies to provide medical advancements, it has been much slower to adopt technology within its marketing efforts, mostly relying on traditional channels and methods. However, the decreasing effectiveness of these traditional channels, given changing physician, patient and consumer trends in todayâ€™s increasingly digital society, is forcing an evolution of pharmaceutical marketing strategies. The report examines how the effective implementation of various digital marketing approaches, in conjunction with traditional channels in an integrated multichannel marketing strategy, has the ability to expand marketing reach, increase audience engagement, provide higher return on investment (ROI) and improve methods of tracking ROI for pharmaceutical companies. The report features an overview of the various marketing channels available to pharma, and examines the factors driving change within this field. It analyzes how a wide range of digital marketing methods can be effectively integrated into a synergistic multichannel marketing strategy that allows both traditional and newer channels to complement each other. Analysis of the main challenges and risks associated with digital marketing methods, in addition to potential solutions and approaches to overcoming them, is provided. Real-world case studies of marketing strategies and campaigns employed by pharma are also included. GBI Research conducted extensive research in order to provide a comprehensive view of the evolving pharmaceutical marketing landscape. In addition to garnering views from internal experts GBI Research conducted an extensive interview with pharmaphorum CEO and founder Paul Tunnah, who is an experienced industry thought leader and advisor with a specialist focus on cross-stakeholder communication, digital/social media engagement and collaborative innovation. Based on the totality of our research, strategic recommendations and guidelines are provided throughout the report for the effective implementation of digital marketing strategies within a coherent overall multichannel marketing strategy. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising areas in the market and exploit key business opportunities. Scope - What are the different marketing channels available to pharma? - What factors are driving change in the traditional pharma marketing strategy? - What is a multichannel marketing strategy? What are the benefits, and how can they be implemented effectively? - What are the different digital marketing strategies that pharma can utilize in order to keep pace with changing needs, and maintain ROI? How can these be implemented effectively? - What are the main challenges and risks associated with digital marketing methods, and what are some potential solutions and approaches to overcoming these? - What digital marketing strategies and campaigns have been employed by pharma in recent years? - What are the key strategic recommendations and guidelines for digital marketing as part of an integrated multichannel marketing strategy? Reasons to buy - Understand how and why pharmaceutical marketing is evolving - Gain insights into various digital marketing strategies, their benefits and key features, and recommendations on how to effectively implement them - Assess examples of approaches taken by other companies in the field - Understand the challenges and risks involved in pharma digital marketing, and ways in which you can plan for these challenges and minimize risk
|Big Data - Embracing Data to Transform Healthcare and Pharma Commercial Strategy - Featuring Expert Panel Views from Industry Survey 2016|
Big Data: Embracing Data to Transform Healthcare and Pharma Commercial Strategy - Featuring Expert Panel Views from Industry Survey 2016 Summary GBI Researchâ€™s latest report," Big Data: Embracing Data to Transform Healthcare and Pharma Commercial Strategy â€“ Featuring Expert Panel Views from Industry Survey 2016" provides a comprehensive analysis of the Big Data landscape. GBI Research conducted an extensive industry survey of 73 experts from the pharmaceutical and healthcare industries â€“ including both organizations that already utilize Big Data and those that do not. Our survey gathered experience and opinion on the use of Big Data, and insights on key trends for the present and future use of the technology within healthcare. The findings from the survey and results from secondary research efforts have been amalgamated with GBIâ€™s own analytical views to provide an assessment that is comprehensive in outlook. Big Data refers to any data set that is too large to store, process or analyze using traditional database software and hardware. It can have a significant impact on all aspects of the pharmaceutical and healthcare sector, and companies are making large investments to leverage the technology more effectively. Big Data has been a buzzword for many years, but it is no longer merely an abstract concept that could provide future benefits, as it is already providing competitive advantages for a variety of organizations. As such, companies that ignore its potential may fall behind their peers in our increasingly data-intensive world. The report features an overview of Big Data and its place within healthcare. It examines the factors driving and necessitating the use of the technology within this industry, and provides detailed examples of how different Big Data sources and analytics techniques could be used to provide direct benefits to pharmaceutical companies, healthcare institutions and patients. There is also an analysis of the main challenges surrounding the technology, as well as detailed real-world case studies of how major companies already implement Big Data and deal with some of the challenges. Finally, based upon the totality of our survey results and research, strategic recommendations and guidelines are provided for the effective implementation of Big Data within healthcare. The results of GBIâ€™s latest industry survey provide insightful analyses from different expert panels, including those that already use Big Data and those that do not, key regional markets, and respondents from within the pharmaceutical industry and those from the wider healthcare industry. The survey examined key issues, such the areas where organizations are currently utilizing Big Data, where they believe it can have the most impact, the main barriers to use and driving factors, likelihood of increasing investment within the next five years, and overall stance on the use of the technology within healthcare. GBI Research conducted extensive research in order to provide a comprehensive view of Big Data for healthcare landscape. This new report adds to our unique portfolio of trusted industry analyses that enable our clients to assess the most promising areas in the market and exploit key business opportunities. Scope - What is Big Data? What is its place within healthcare, and what are the main data sources? - How prevalent is the use of Big Data in healthcare? - What are the main driving factors necessitating the use of Big Data in healthcare? What is the relative importance of these factors according to industry? - What are examples of the commercial benefits that the use of Big Data and analytics can provide, in different aspects of the industry? - In which areas are organizations currently using Big Data, and where do they feel it will have the most impact in the next five years? - What are the main challenges associated with Big Data in healthcare? What is the relative importance of these factors according to industry? For the organizations that do not yet utilize Big Data, what specific reasons have led to their decision not to do so? - How do major pharmaceutical and healthcare companies use Big Data in the real world? What are some of the main partnerships between Big Pharma and technology companies? What is the underlying technical architecture of Big Data in healthcare? - What is the likelihood that organizations that already use Big Data will increase their investment within the next five years? Will those that do not currently invest in the technology begin doing so in the next five years? - How can Big Data be effectively implemented within an organization? - What is the overall stance of various experts in the healthcare field on the use of Big Data in healthcare? Reasons to buy This report will allow you to - - Gain insightful analyses and comprehensive understanding of Big Data in healthcare - Understand the key drivers necessitating the use of Big Data and the main barriers to implementation - Understand the views of 73 organizations within the industry on Big Data, and assess real-world case studies - Assess the most relevant uses of Big Data within your company, and effective ways of implementing Big Data strategie
|Pharmaceutical Lifecycle Management - Strategies in 2017|
Pharmaceutical Lifecycle Management Strategies in 2017 Summary Pharmaceutical lifecycle management (LCM) is the process of managing the entire lifecycle of a product including its research, design and manufacture, service and disposal. LCM is a well-established tool to maximize sales throughout the product lifecycle and acts as a competitive edge to provide greater profitability and retain market share as the patent expiry or market exclusivity rights of products approaches. LCM planning will continue to be at the forefront of the pharmaceutical industryâ€™s efforts to address declining R&D productivity, stricter reimbursement demands and increasing generic and branded competition. Pharmaceutical industry continues to face a variety of threats and challenges. These are not new challenges, as they are mostly the result of a wide variety of economic, operational and commercial issues that in many cases have been overlooked, accumulating over decades and increasingly gaining momentum. Companies in the pharmaceutical industry invest significant capital and resources into preserving the patent life and the subsequent profits of products which take several years to produce. The potential rapid revenue losses that innovator companies in the pharmaceutical industry can experience due to generic competition calls for the incorporation of sophisticated strategies that allow for maximizing a productâ€™s lifetime value. Important challenges include pricing pressures, rising development costs, stringent regulatory and reimbursement policies, declining R&D productivity and drug patent cliffs (the immediate decline in sales after the patent expiration). These issues, particularly the productivity gap, leave pharmaceutical companies exposed to generic and biosimilar competition, which can erode a significant percentage of their sales and market share within a short period of time. Companies risk losing up to 90% of the revenue of some of their biggest products to generic and biosimilar competition. The report â€œPharmaceutical Lifecycle Management Strategies in 2017â€ provides a comprehensive assessment of product lifecycle (LCM) management strategies that are being implemented by pharmaceutical companies around the world. In depth, this report enables the following - - Helps to investigate a wide range of commercial, developmental, legal and regulatory strategies. - Provides deep analysis into the rationale for implementing LCM strategies, as well as the challenges, risks and commercial opportunities. - To understand the key challenges that the pharmaceutical industry has been facing in recent years. Scope - What is driving the need for effective LCM strategies in the pharmaceutical industry? - What are the most common LCM strategies being implemented? - What are the business opportunities and commercial rewards arising from the implementation of LCM strategies? - What are the key factors that impact the choice of LCM strategy? - What strategies have Big Pharma companies implemented in recent years to preserve revenues and market share? Key Reasons to Purchase This report will allow you to - - Gain insights into the rationale for implementing LCM strategies, alongside their key challenges, risks and potential benefits. - Understand the key challenges that the pharmaceutical industry has been facing in recent years - Assess real-world examples of successful strategies implemented in the past, and the key factors that determined their success. - Obtain information on strategies for products currently in development.
|Mobile Health mHealth Technologies - Global Market Prospects - Featuring Expert Panel Views from Industry Survey 2017|
Mobile Health (mHealth) Technologies: Global Market Prospects - Featuring Expert Panel Views from Industry Survey 2017 Summary mHealth is often regarded as a branch of eHealth, which has been defined by the European Commission as â€œThe use of modern information and communication technologies to meet needs of citizens, patients, healthcare professionals, healthcare providers, as well as policy makers.â€ Within this, the mHealth branch focuses specifically on the use of mobile technology. Rapid advances in new mobile devices, the expansion of communication network coverage and the reduction in the retail price of wireless technologies have all helped in making mHealth solutions and services a reality. The uptake of mHealth technologies will increase in the near future as the overall healthcare industry continues to shift towards value-based medicine, and the need to clearly demonstrate the value and effectiveness of medical interventions grows. Support from healthcare professionals (HCP), reimbursement entities and government agencies will also increase as the body of literature documenting the wide range of benefits of mHealth continues to grow. Furthermore, the continued acceleration of mobile penetration at a global level will continue to make mHealth services and solutions possible, even in the most remote areas. Non-profit organizations such as the mHealth Alliance and the World Healthcare Organization (WHO) advocate the increased use of mHealth, particularly in underserved communities where poor infrastructure, non-availability of experts and doctors, and lack of medical education have hampered the provision of healthcare. A key benefit of mHealth technologies, if not the most important one, is their ability to fulfill this unmet need and provide continuous healthcare at a distance. Moreover, mHealth technologies such as dose reminders can improve healthcare outcomes and reduce complications in chronic conditions by optimizing treatment compliance. For instance, 95% of diabetic cases are estimated to be self-managed, and mobile and Bluetooth glucose sensors have been developed to help patients to optimize drug dosing, reducing the risk of non-compliance and improving life expectancy (Diabetes UK, 2009). Significant advances in devices, sensors, monitors and mobile applications (apps) have seen the development of cost-effective portable diagnostics to remotely manage and monitor disease. The report â€œMobile Health (mHealth) Technologies: Global Market Prospects - Featuring Expert Panel Views from Industry Survey 2017â€ provides a comprehensive analysis of the mHealth landscape. The survey gathered experience and opinion on the use of mHealth, and insights on key trends for the present and future use of these technologies, particularly within the pharmaceutical industry. In depth, this report provides the following analysis - - Provides an analytical review of the most important needs and trends driving, or preventing, the use of mHealth technologies. It utilizes extensive secondary and internal research, in addition to our proprietary industry survey, in which respondents were asked to rank the relative importance of various market drivers and restraints. Additional survey insights include key reasons preventing organizations from investing in mHealth initiatives, including views from experts based in different geographical markets. - Explores how mHealth solutions and services could be used to provide direct benefits for pharmaceutical companies, healthcare institutions, healthcare providers and patients. Additionally, it provides survey analyses of the most common areas where mHealth solutions are being utilized within the pharmaceutical value chain, and where these solutions will have the most impact in the near future. - Provides a detailed analysis of the most promising geographical markets for mHealth technologies from 2017 to 2021. It provides results from our industry survey, in which respondents were asked to identify the most promising emerging markets for mHealth solutions and services over the next five years. - Provides strategic considerations for the effective implementation of mHealth initiatives, based on the totality of our industry survey results and a range of secondary and internal research. These include broad guidelines for different aspects of the implementation process such as: workflow strategies, revenue model considerations, governance, monitoring and human resource strategies. Scope - What are mHealth technologies? What is their place within the pharmaceutical industry? - How prevalent is the use of mHealth technologies in the pharmaceutical, healthcare and healthcare IT industries? - What are the main driving factors necessitating the use of mHealth? What is the relative importance of these factors? - What are the commercial benefits that the use of mHealth solutions and services can provide across the pharmaceutical value chain? - In which areas are organizations currently using mHealth, and where do they feel it will have the most impact in the next five years? - What are the main challenges associated with mHealth technologies? What is the relative importance of these factors across key geographical markets? For the organizations that do not yet utilize mHealth solutions, what specific reasons have led to this decision? - What is the likelihood that organizations that already use mHealth will increase their investment within the next five years? Will those that do not currently invest in the technology begin doing so over this period? - How can mHealth initiatives be effectively implemented within an organization? - What is the overall opinion of industry experts on the use of mHealth technologies? Key Reasons to Purchase - Gain insightful analyses and comprehensive understanding of mHealth technologies - Understand the key drivers necessitating the use of mHealth and the main barriers to implementation - Understand the views of 65 different organizations within the industry on mHealth - Assess the most relevant uses of mHealth solutions and services within your company, and effective ways of implementing mHealth initiative
|Robotic Surgical Systems - Medical Devices Pipeline Assessment, 2017|
Robotic Surgical Systems consist of robotic arms with laparoscopic instruments, where doctor sits a few feet away from operating table at a computer console viewing 3D visual of operating region. GlobalData's Medical Devices sector report, â€œRobotic Surgical Systems - Medical Devices Pipeline Assessment, 2017" provides comprehensive information about the Robotic Surgical Systems pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. The Robotic Surgical Systems Pipeline Assessment report provides key information and data related to: Extensive coverage of the Robotic Surgical Systems under development. Review details of major pipeline products which include product description, licensing and collaboration details and other developmental activities including pipeline territories, regulatory paths and estimated approval dates. Reviews of major players involved in the pipeline product development. Provides key clinical trial data related to ongoing clinical trials such as trial phase, trial status, trial start and end dates, and, the number of trials of the major Robotic Surgical Systems pipeline products. Review of recent developments in the segment / industry. The Robotic Surgical Systems Pipeline Assessment report enables you to: Access significant competitor information, analysis, and insights to improve your R&D strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Identify and understand important and diverse types of Robotic Surgical Systems under development. Formulate market-entry and market expansion strategies. Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline. Companies Mentioned Endomaster Pte Ltd Medrobotics Corp Memic Innovative Surgery Ltd. Technische Universiteit Eindhoven TransEnterix, Inc. Virtual Incision Corporation
|MediPoint: Robotic Surgical Systems - Global Analysis and Market Forecasts|
Surgical robotic systems are technological developments that use robotic systems to aid in surgical procedures. The global surgical robotic systems market will be strongly driven by the increase in the number of procedures that can be carried out using surgical robotic systems and new companies entering the market with their own products. Global market is dominated by Intuitive Surgical. Scope Overview of the Surgical Robotics Systems market, including reimbursement trends and M&A analysis Annualized total market revenue by type of device, procedure trends, and market outlooks by region through 2024. Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement considerations, evaluating market access in each region covered in the report, and implications of the emerging technologies on the market. Pipeline analysis: Comprehensive data split across different stages of development and analysis of emerging trends in design. Analysis of the current and future market competition in the global Surgical Robotics Systems market. Insightful review of the key industry drivers, barriers, and challenges. Each trend is independently researched to provide qualitative analysis of its implications. Reasons to buy The report will enable you to: Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global Surgical Robotics Systems market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Foams market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Track device sales in the global and regional Surgical Robotics Systems market from 2017-2024. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. Companies Mentioned Auris Surgical Robotics Versius Surgical Robotic System Medrobotics Corp Flex Robotic System TransEnterix Intuitive Surgical Titan Medical Verb Surgical
|Global Mycoplasma Testing Market By Product & Services (Kits & Reagent and Instruments), Technique (PCR, ELSA, Enzymatic Methods, and DNA Staining), Application (Cell Line Testing and Virus Testing), End User (Pharmaceutical Companies and Cell Banks)and Regional Market Size, Status and Forecast to 2025|
Market Overview: The global Mycoplasma Testing Market was valued at USD 465.30 million in 2016 and is projected to reach USD 1337.73million by 2025, growing at a CAGR of 12.45% from 2017 to 2025. Mycoplasma contamination is a constant risk for the cell culturist. Mycoplasma is small, simple bacteria which lack a cell wall and represent one of the most prevalent and serious sources of cell line contamination. Mycoplasma contamination is invisible with no discernible change in turbidity or pH. Sample Infographics: Market Dynamics: 1. Market Drivers 1.1 Increasing Growth and Government Support for Pharmaceutical and Biotechnology Industries 1.2 Strong Trend of R&D Investments in Life Sciences 1.3 Cell Culture Contaminationâ€”A Major Concern for Laboratories 2. Market Restraints 2.1 High Degree of Consolidation Acts as an Entry Barrier for New Entrants 2.2 Stringent Regulatory Frameworks and Time-Consuming Approval Processes for Pharmaceutical and Biotechnology Companies Market Segmentation: 1. Global Mycoplasma TestingMarket, by End User: 1.1 Pharmaceutical and Biotechnology Companies 1.2 Contract Research Organizations 1.3 Academic Research Institutes 1.4 Cell Banks 1.5 Other End Users 2. Global Mycoplasma TestingMarket, by Application: 2.1 Cell Line Testing 2.2 Virus Testing 2.3 End-Of-Production Cell Testing 2.4 Other Applications 3. Global Mycoplasma TestingMarket, by Technique: 3.1 PCR 3.2 Elisa 3.3 Direct Assays 3.4 Indirect Assays 3.5 Dna Staining 3.6 Microbial Culture Techniques 3.7 Enzymatic Methods 4. Global Mycoplasma Testing Market, by Product and Services: 4.1 Kits and Reagents 4.1.1 PCR Assays 4.1.2 Nucleic Acid Detection Kits 4.1.3 Elimination Kits & Reagents 4.1.4 Stains 4.1.5 Standards & Controls 4.1.6 Other Kits & Reagents 4.2 Instruments 4.3 Services 5. Global Mycoplasma Testing Market, by Region: 5.1 North America (U.S., Canada, Mexico) 5.2 Europe (Germany, UK, France, Rest of Europe) 5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific) 5.4 Latin America (Brazil, Argentina, Rest of Latin America) 5.5 Middle East & Africa Competitive Landscape: The major players in the market are as follows: 1. Charles River Laboratories International, Inc. 2. Merck KGaA 3. Lonza Group Ltd. 4. Roche Diagnostics (Division of F. Hoffman-LA Roche Ltd.) 5. SGS S.A. 6. Thermo Fisher Scientific Inc. 7. American Type Culture Collection 8. Biounique Testing Laboratories Inc. 9. Invivogen 10. Promocell GmbH 11. Biological Industries Israel Beit Haemek Ltd. 12. Wuxi Apptec 13. NorgenBiotek Corporation These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market. Research Methodology: Research study on the Mycoplasma TestingMarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review. The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our sales team.
|Global Single-cell Analysis Market By Product (Consumables and Instruments), Cell Type (Human and Animal), Technique (Flow Cytometry, NGS, PCR, and Mass Spectrometry), Application (Cancer, Neurology, NIPD, IVF, and CTCs), End User and Regional Market Size, Status and Forecast to 2025|
Market Overview: The global Single-cell Analysis Market was valued at USD 1.38 billion in 2016 and is projected to reach USD 5.41billion by 2025, growing at a CAGR of 16.43% from 2017 to 2025. In the field of cellular biology, single-cell analysis is the study of: genomics, transcriptomics, proteomics and metabolomics at the single cell level. Due to increased prevalence of Biotechnology and Biomedical application in Healthcare, the market is expected to grow at a high rate. Sample Infographics: Market Dynamics: 1. Market Drivers 1.1 Technological Advancements in Single-Cell Analysis Products 1.2 Increasing Government Funding for Cell-Based Research 1.3 Growing Biotechnology and Biopharmaceutical Industries 1.4 Wide Applications of Single-Cell Analysis in Cancer Research 1.5 Growing Focus on Personalized Medicine 1.6 Increasing Incidence and Prevalence of Chronic and Infectious Diseases 2. Market Restraints 2.1 High Cost of Single-Cell Analysis Products Market Segmentation: 1. Global Single-cell AnalysisMarket, by End User: 1.1 Academic & Research Laboratories 1.2 Biotechnology and Pharmaceutical Companies 1.3 Hospitals and Diagnostic Laboratories 1.4 Cell Banks and Ivf Centers 2. Global Single-cell AnalysisMarket, by Application: 2.1 Research Applications 2.1.1 Cancer Research 2.1.2 Immunology Research 2.1.3 Neurology Research 2.1.4 Stem Cell Research 2.1.5 Other Research Applications 2.2 Medical Applications 2.2.1 Non-Invasive Prenatal Diagnosis 2.2.2 in Vitro Fertilization 2.2.3 Circulating Tumor Cell Detection 3. Global Single-cell AnalysisMarket, by Technique: 3.1 Flow Cytometry 3.2 Next-Generation Sequencing 3.3 Polymerase Chain Reaction 3.4 Microscopy 3.5 Mass Spectrometry 3.6 Other Techniques 4. Global Single-cell Analysis Market, by Cell Type: 4.1 Human Cells 4.2 Animal Cells 4.3 Microbial Cells 5. Global Single-cell AnalysisMarket, by Product: 5.1 Instruments 5.1.1 Flow Cytometers 5.1.2 NGS Systems 5.1.3 PCR Instruments 5.1.4 Spectrophotometers 5.1.5 Microscopes 5.1.6 Cell Counters 5.1.7 HCS Systems 5.1.8 Microarray Systems 5.1.9 Other Instruments 5.2 Consumables 5.2.1 Beads 5.2.2 Microplates 5.2.3 Reagents 5.2.4 Assay Kits 126.96.36.199 Immunoassays 188.8.131.52 Cell-Based Assays 5.2.5 Others consumables 6. Global Single-cell Analysis Market, by Region: 6.1 North America (U.S., Canada, Mexico) 6.2 Europe (Germany, UK, France, Rest of Europe) 6.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific) 6.4 Latin America (Brazil, Argentina, Rest of Latin America) 6.5 Middle East & Africa Competitive Landscape: The major players in the market are as follows: 1. Merck KGaA 2. Thermo Fisher Scientific, Inc. 3. Becton, Dickinson and Company 4. Beckman Coulter, Inc. (A Subsidiary of Danaher Corporation) 5. Bio-Rad Laboratories, Inc. 6. Qiagen N.V. 7. Illumina, Inc. 8. GE Healthcare 9. Agilent Technologies 10. Fluidigm Corporation These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market. Research Methodology: Research study on the Single-cell AnalysisMarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review. The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our sales team.
|Global Digital PCR and Real-time PCR (qPCR) Market By Technology (qPCR, dPCR), Product (Instrument, Reagent), Application (Oncology, Blood Testing, Pathogen Detection, Research, Forensic), End User (Hospital, Diagnostic Center, Academia, CRO).and Regional Market Size, Status and Forecast to 2025|
Market Overview: The global Digital PCR and Real-time PCR (qPCR) Market was valued at USD 3.17 billion in 2016 and is projected to reach USD 6.79billion by 2025, growing at a CAGR of 8.83% from 2017 to 2025. Factors such as the growth in the geriatric population, rising incidence of infectious diseases and genetic disorders, technological advancements in the field of PCR, and increasing investments and availability of funds for PCR-based research are driving the growth of the global dPCR and qPCR market. Sample Infographics: Market Dynamics: 1. Market Drivers 1.1 Rising Incidences of Infectious Diseases and Genetic Disorders 1.2 Technological Advancement in PCR Technologies 1.3 Increasing Public-Private Investments, Funds, and Grants 1.4 Increasing Use of Biomarker Profiling for Disease Diagnostics 1.5 Successful Completion of the Human Genome Project 2. Market Restraints 2.1 High Device Costs Associated With dPCR 2.2 Technical Limitations of qPCR and dPCR Techniques Market Segmentation: 1. Global Digital PCR and Real-time PCR (qPCR)Market, by Product and Services: 1.1 dPCR Products and Services 1.1.1 dPCR Instruments 1.1.2 dPCR Reagents and Consumables 1.1.3 dPCR Software and Services 1.2 qPCR Products and Services 1.2.1 qPCR Reagents and Consumables 1.2.2 qPCR Instruments 1.2.3 qPCR Software and Services 2. Global Digital PCR and Real-time PCR (qPCR)Market, by Technology: 2.1 Quantitative PCR (qPCR) 2.2 Digital PCR (dPCR) 3. Global Digital PCR and Real-time PCR (qPCR)Market, by End User: 3.1 Digital PCR (dPCR) End Users 3.1.1 Research Laboratories and Academic Institutes 3.1.2 Hospitals and Diagnostic Centers 3.1.3 Pharmaceutical and Biotechnology Companies 3.1.4 Clinical Research Organizations 3.1.5 Forensic Laboratories 3.2 Quantitative PCR (qPCR) End Users 3.2.1 Hospitals and Diagnostic Centers 3.2.2 Research Laboratories and Academic Institutes 3.2.3 Pharmaceutical and Biotechnology Companies 3.2.4 Clinical Research Organizations 3.2.5 Forensic Laboratories 4. Global Digital PCR and Real-time PCR (qPCR) Market, by Application: 4.1 qPCR and dPCR applications 4.1.1 Clinical Applications 184.108.40.206 Pathogen Testing 220.127.116.11 Oncology Testing 18.104.22.168 Blood Screening 22.214.171.124 Other Clinical Applications 4.1.2 Research Applications 4.1.3 Forensic Applications 5. Global Digital PCR and Real-time PCR (qPCR)Market, by Region: 5.1 North America (U.S., Canada, Mexico) 5.2 Europe (Germany, UK, France, Rest of Europe) 5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific) 5.4 Latin America (Brazil, Argentina, Rest of Latin America) 5.5 Middle East & Africa Competitive Landscape: The major players in the market are as follows: 1. Hoffman-La Roche Ltd. 2. Thermo Fisher Scientific, Inc. 3. Bio-Rad Laboratories, Inc. 4. Qiagen N.V. 5. Takara Bio, Inc. 6. Agilent Technologies, Inc. 7. BiomÃ©rieux S.A. 8. Fluidigm Corporation 9. Danaher Corporation 10. ABBott Laboratories 11. Merck KGaA 12. Becton Dickinson and Company 13. Promega Corporation 14. Meridian Bioscience, Inc. (Bioline Reagents Ltd.) 15. Analytik Jena AG (Endress+Hauser Ag) These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market. Research Methodology: Research study on the Digital PCR and Real-time PCR (qPCR)Marketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review. The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our sales team.
|Global Injectable Drug Delivery Technology Market Size, Status and Forecast 2025|
This report studies the global Injectable Drug Delivery Technology market, analyzes and researches the Injectable Drug Delivery Technology development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like Alkermes Genentech Bend Research QLT Endocyte BIND Biosciences UCB Group (UCB) Presage Bioscience Polymer Factory MicroCHIPS Pearl Therapeutics Piedmont Pharmaceuticals Zogenix Liquidia Technologies Impax Laboratories Boehringer Ingelheim Crossject Medical Technology Apogee Technology Pulmatrix Medicago Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, the product can be split into Conventional Drug Delivery Novel Drug Delivery Market segment by Application, Injectable Drug Delivery Technology can be split into Cardiovascular Diseases Diabetes Regenerative Medicine Oncology Pain Management Hepatitis C Auto Immune Disorders Others If you have any special requirements, please let us know and we will offer you the report as you want.
|Global Cellular Health Screening/Health Testing Market By Type (Single (Telomere, Oxidative Stress, Inflammation, Heavy Metal), Multitest), Sample (Blood, Saliva, Serum, Urine), Collection Site (Home, Office, Hospital, Diagnostic Labs)and Regional Market Size, Status and Forecast to 2025|
Market Overview: The global Cellular Health Screening/Health Testing Marketwas valued at USD 1.81 billion in 2016 and is projected to reach USD 4.84billion by 2025, growing at a CAGR of 9.65% from 2017 to 2025. It can be used to assess inflammatory conditions, such as allergies, asthma, arthritis, autoimmune conditions, or inflammatory digestive problems. It can also be used to monitor response to treatment. Increase in Healthcare awareness and prevalence of chronic diseases is the key driver to the particular sector of the healthcare diagnostics market. Sample Infographics: Market Dynamics: 1. Market Drivers 1.1 Increasing Adoption of Telomere Performance Programs for Leading A Healthy Life 1.2 Growingsignificance of healthy life expectancy 1.3 Growing concerns from Govt. towards preventive healthcare 1.4 Rise in geriatric population 1.5 Increased Research and Development projects 1.6 Prevalence of chronic diseases 2. Market Restraints 2.1 Fragility of samples making the transportation difficult 2.2 Cost differences and instability of kits Market Segmentation: 1. Global Cellular Health Screening/Health Testing Market, by Sample Type: 1.1 Blood samples 1.2 Urine Samples 1.3 Saliva Samples 1.4 Others 2. Global Cellular Health Screening/Health Testing Market, by Sample Collection sites: 2.1 At Home 2.2 In-Office 2.3 Others 3. Global Cellular Health Screening/Health Testing Market, by ProductType: 3.1 Single Test Panels 3.1.1 Telomere Tests 3.1.2 Oxidative Stress Tests 3.1.3 Inflammation Tests 3.1.4 Heavy Metals Tests 3.2 Multi-Test Panels 4. Global Cellular Health Screening/Health Testing Market, by Region: 4.1 North America (U.S., Canada, Mexico) 4.2 Europe (Germany, UK, France, Rest of Europe) 4.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific) 4.4 Latin America (Brazil, Argentina, Rest of Latin America) 4.5 Middle East & Africa Competitive Landscape: The major players in the market are as follows: 1. Telomere Diagnostics, Inc. (TDX) 2. Spectracell Laboratories 3. Life Length 4. Repeat Diagnostics Inc. (Repeat DX) 5. Titanovo 6. Cell Science Systems 7. Quest Diagnostics 8. Labcorp Holdings 9. Biorefrence Laboratories 10. Cleveland Heartlab, Inc. 11. Genova Diagnostics 12. Zimetry LLC 13. Immundiagnostik AG 14. Segterra, Inc. 15. DNA Labs India These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market. Research Methodology: Research study on the Cellular Health Screening/Health Testing Marketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review. The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our sales team.